Clinical Trials » Macular Degeneration
ACU-4429, Visual Cycle Modulator, for Dry AMD: Acucela
|
RECRUITING Description: Acucela is conducting a Phase II clinical trial in the U.S. of ACU-4429, an orally administered visual cycle modulator, for the treatment of dry age-related macular degeneration (AMD). A total of 84 people may be enrolled in the study. By slowing the visual cycle, the drug is intended to reduce the build-up of toxic by-products in the retina (retinal pigment epithelium) that cause vision loss in dry AMD and potentially other retinal conditions. The drug has shown promising results in a preclinical study and a Phase I clinical trial. Trial Status: Ongoing, recruiting. Articles: Promising Dry AMD Treatment Moves into Phase II Clinical Trial Partial List of Participation Criteria:
Clinical Trial Contacts: Charles Yoon (310) 289-2478 ext. 112 Retina-Vitreous Associates Medical Group Beverly Hills, CA Stephanie Pace, R.N. (386) 366-6425 Covance Clinical Research Unit Daytona Beach, FL Cheryl Kiesel, C.C.R.C. (239) 938-1284 National Ophthalmic Research Unit Fort Meyers, FL Amelita Sellona (808) 441-6394 Covance Clinical Research Unit Honolulu, HI Jennifer Upton (214) 647-9314 Covance Clinical Research Unit Dallas, TX Additional Information: ACU-4429 clinical trial listing on ClinicalTrials.gov |
